In January 2024, InvestingPro’s Fair Value model identified Vaxcyte, Inc. (NASDAQ:PCVX) as significantly overvalued at $60 per share. This analysis proved remarkably accurate, as the stock has since ...

The premium for the US 10-year Treasury yield continued to fall in August relative to the “fair value” estimate. CapitalSpectator.com’s multi-factor fair-value model has been forecasting for some time ...

Investing.com's Fair Value analysis has once again demonstrated its effectiveness in identifying market opportunities, this time with dating app provider Bumble Inc. (NASDAQ:BMBL). The proprietary ...

When InvestingPro’s Fair Value model flagged Doximity, Inc. (NYSE:DOCS) as significantly overvalued in February 2025, the digital health platform was riding high at $79.23 per share. Fast forward to ...

Invesco (IVZ) stock analysis: management-fee model, flat cash flow, fair-value ~$29, $1B FCF potential but weak growth. Read ...

Gladstone Commercial’s story has just been refreshed, with new research keeping the model fair value anchored at US$12.50 while tweaking some of the inputs behind that number. The slight reduction in ...

Analysts have refreshed their view on Veritone, lifting the fair value estimate from US$11.20 to US$12.00, while making only small tweaks to the underlying model inputs. The discount rate has shifted ...